Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Biogen Ma Inc patents


Recent patent applications related to Biogen Ma Inc. Biogen Ma Inc is listed as an Agent/Assignee. Note: Biogen Ma Inc may have other listings under different names/spellings. We're not affiliated with Biogen Ma Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Biogen Ma Inc-related inventors


 new patent  Methods for improved measurements of brain volume and changes in brain volume

Methods of the disclosure may include obtaining a first set of medical images at a first time point and a second set of medical images at a second time point, each set including at least two medical images. First and second algorithms may be used to calculate, respectively, first and... Biogen Ma Inc

Methods of treating multiple sclerosis

Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate,... Biogen Ma Inc

Heterobicyclic sphingosine 1-phosphate analogs

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.... Biogen Ma Inc

Methods of treating multiple sclerosis

Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate,... Biogen Ma Inc

Human anti-tau antibodies

Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used... Biogen Ma Inc

Apparatus for compound dispersion

Methods and apparatuses for dispersing a compound within the patient are described. In one embodiment, an effective amount of a compound may be present in the cerebrospinal fluid of a patient and a force may be applied to the torso of the patient sufficient to enhance the convection of the... Biogen Ma Inc

Humanized anti-alpha v beta 5 antibodies and uses thereof

Humanized antibodies and antibody fragments that bind to αvβ5 are disclosed. Also disclosed are methods of using the disclosed antibodies and antibody fragments to treat or prevent αvβ5-mediated diseases.... Biogen Ma Inc

Compositions and methods for detection of smn protein in a subject and treatment of a subject

Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy. Also provided are kits for detecting the amount of... Biogen Ma Inc

Methods of treating multiple sclerosis

Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate,... Biogen Ma Inc

Diterpenoid derivatives and methods of use thereof

Provided herein are compounds of formula (I) and compositions containing the compounds. The compounds and compositions are useful in the methods of treating, amelioration or prophylaxix of diseases associated with Nrf2/NF-κB pathways. The diseases associated include, but are not limited to a fibrotic disease such as lung fibrosis, liver fibrosis,... Biogen Ma Inc

Methods and compositions for controlling antibody aggregation

Disclosed herein are methods of purifying monoclonal antibodies and related compositions.... Biogen Ma Inc

Anti-gpiib/iiia antibodies and uses thereof

Antibodies and antibody fragments that specifically bind to glycoprotein IIb/IIIa (GPIIb/IIIa) are disclosed. Chimeric molecules comprising such antibodies or antigen-binding fragments are also disclosed. In addition, methods of using the disclosed antibodies, antibody fragments, and chimeric molecules, e.g., to target agents to platelets and for the treatment or prevention of... Biogen Ma Inc

Anti-glycoprotein iib/iiia antibodies

Antibodies and antigen-binding antibody fragments that bind to GPIIb/IIIa and chimeric polypeptides comprising these binding molecules are disclosed. Some of these antibodies and antigen-binding antibody fragments preferentially bind GPIIb/IIIa on activated platelets while others do not show a preference for binding GPIIb/IIIa on resting versus activated platelets. Some of these... Biogen Ma Inc

Antibodies to vla-1

Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.... Biogen Ma Inc

Hypotaurine, gaba, beta-alanine, and choline for control of waste byproduct accumulation in mammalian cell culture process

The present invention pertains to a cell culture medium comprising hypotaurine, GABA, and/or beta-alanine or the combination of choline and hypotaurine, GABA, and/or beta-alanine as media supplements which is shown to control viability, growth, and waste byproduct accumulation. The present invention further pertains to a method of producing a polypeptide... Biogen Ma Inc

Copper supplementation for control of glycosylation in mammalian cell culture process

The present invention pertains to a cell culture medium comprising copper as a media supplement, which was shown to control recombinant protein glycosylation and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large... Biogen Ma Inc

Systems and methods for characterization of multiple sclerosis

Methods and systems to characterize multiple sclerosis (MS) in a subject, e.g., in a subject having a progressive form of MS are disclosed.... Biogen Ma Inc

Injector lockout prevention device

A device that prevents the accidental activation and lockout of an autoinjector. In illustrative embodiments, a resistance unit is configured to resist deployment of the needle until a critical force is applied by the user to the autoinjector, at which point, the resistance of the resistance unit is overcome. Continuous... Biogen Ma Inc

Systems and methods for assessing therapeutic proteins

Systems and methods for assessing the oxidation status of a pharmaceutical preparations are provided herein. Methods provided herein are particularly useful for assessing pharmaceutical preparations comprising therapeutic proteins (e.g., therapeutic antibodies).... Biogen Ma Inc

Biomarkers predictive of lupus progression and uses thereof

Methods, systems and kits to detect and/or quantify lupus and disease progression in a subject having, or at risk of having, lupus are disclosed.... Biogen Ma Inc

Optimized factor ix gene

The present invention provides codon optimized Factor IX sequences, vectors and host cells comprising codon optimized Factor IX sequences, polypeptides encoded by codon optimized Factor IX sequences, and methods of producing such polypeptides. The present invention also provides methods of treating bleeding disorders such as hemophilia comprising administering to the... Biogen Ma Inc

Methods of preventing and removing trisulfide bonds

The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of... Biogen Ma Inc

Methods of treating inflammatory and autoimmune diseases with natalizumab

Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the... Biogen Ma Inc

Bicyclic aryl sphingosine 1-phosphate analogs

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.... Biogen Ma Inc

Pegylation method

The present invention relates to a method for PEGylating interferon beta.... Biogen Ma Inc

Anti-cd40 antibodies and uses thereof

Antibodies and antibody fragments that bind to human CD40 and inhibit interaction between CD40 and its ligand, CD40L are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit hyperactivation of B or T cells and treat or prevent disorders such as autoimmune diseases.... Biogen Ma Inc

Fc receptor (fcrn) binding peptides and uses thereof

The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also... Biogen Ma Inc

Medical metering device

A metering device that improves the aseptic transfer of powder and reconstitution fluid into the metering device for medical use. In some implementations, the metering device comprises a housing, containing a metering chamber that defines a volume. The housing also has a connection portion, an extraction portion, and a metering... Biogen Ma Inc

Irak4 inhibiting agents

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.... Biogen Ma Inc

Atx modulating agents

Compounds of formula (I) can modulate the activity of autotaxin (ATX).... Biogen Ma Inc

Trapping reagents for reactive metabolites screening

wherein R1, R2, R4, R5, R6, X and n are as defined herein, and wherein R3 is hydrogen or a sulfur protecting group. Compounds of Formula (I) and (II), wherein R3 is hydrogen, may be useful in methods for detecting a reactive metabolite in a sample, e.g., wherein the metabolite... Biogen Ma Inc

Lyophilized factor ix formulations

The present invention provides, among other things, pre-lyophilization formulations, reconstituted formulations, and lyophilate powder compositions comprising a Factor IX (FIX) polypeptide. The present invention also provides lyophilization methods for producing lyophilate powder comprising a FIX polypeptide. The present invention is directed to a pre-lyophilization formulation comprising: (a) a Factor IX... Biogen Ma Inc

Compounds that are s1p modulating agents and/or atx modulating agents

Compounds of formula (I) can modulate the activity of one or more S1P receptors and/or the activity of autotaxin (ATX).... Biogen Ma Inc

Methods for overcoming glutamine deprivation during mammalian cell culture

The present invention pertains to methods of producing polypeptide of interest in cell cultures lacking glutamine. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with nucleic acid synthesis precursors and/or corticosteroids.... Biogen Ma Inc

06/08/17 / #20170158687

Atx modulating agents

Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for... Biogen Ma Inc

05/11/17 / #20170130186

Cross-scale modeling of bioreactor cultures using raman spectroscopy

Aspect of the disclosure relate to methods of assessing a bioreactor culture that involve determining a culture parameter of the manufacturing-scale bioreactor culture using a model that relates a Raman spectrum to the culture parameter. Related bioreactor system are also provided.... Biogen Ma Inc

04/27/17 / #20170114039

Inhibitors of bruton's tyrosine kinase

The present invention provides a compound, solid forms, and compositions thereof, which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same. The present invention also provides methods of making provided compound and solid forms.... Biogen Ma Inc

04/27/17 / #20170114382

Methods of increasing protein production in mammalian cells

Aspects of the present disclosure provide compositions and methods for increasing protein production in mammalian cells, e.g. methods of increasing mammalian cell expression of a protein of interest, comprising culturing mammalian cells that overexpress a protein of interest and are modified to overexpress a gene encoding Rab 11 or Yap1,... Biogen Ma Inc

03/30/17 / #20170086763

Wearable medical detector

Various embodiments of medical detector systems as well as their methods of operation are disclosed. In one embodiment, one or more detectors are coupled to wearable structures for detecting at least a first tracer within a body portion. In another embodiment, one or more detectors are coupled to a wearable... Biogen Ma Inc

03/30/17 / #20170088835

Compositions and methods for modulation of smn2 splicing

Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.... Biogen Ma Inc

03/23/17 / #20170081623

Gas delivery devices and associated systems and methods

Systems, devices, and methods for the delivery of gas bubbles to liquids are generally described. The devices can include a primary conduit (102) comprising a plurality of openings (104) fluidically connecting an internal flow pathway (106) of the primary conduit to an environment outside the primary conduit. The devices may... Biogen Ma Inc

03/16/17 / #20170073393

Factor viii chimeric proteins and uses thereof

The present invention provides a chimeric protein comprising a first polypeptide which comprises a FVIII protein and a first Ig constant region or a portion thereof and a second polypeptide which comprises a VWF protein comprising the D′ domain and D3 domain of VWF, a XTEN sequence having less than... Biogen Ma Inc

02/23/17 / #20170049904

Polyalkylene polymer compounds and uses thereof

The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C.... Biogen Ma Inc

02/16/17 / #20170044538

Compositions and methods for modulation of smn2 splicing in a subject

Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject.... Biogen Ma Inc

02/09/17 / #20170037126

Sp35 antibodies and uses thereof

Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such... Biogen Ma Inc

02/02/17 / #20170027956

Heterocyclic tyrosine kinase inhibitors

The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same.... Biogen Ma Inc

02/02/17 / #20170029518

Anti-bcma antibodies

This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune... Biogen Ma Inc

02/02/17 / #20170029859

Medium supplements for improved process performance

The present invention pertains to a cell culture medium comprising dextran sulfate or a mixture of dextran sulfate and ferric citrate, and methods of using thereof. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell... Biogen Ma Inc

01/19/17 / #20170016919

Method of assessing risk of pml

The invention relates to methods of assessing a patient's risk of developing Progressive Multifocal Leukoencephalopathy (PML).... Biogen Ma Inc

01/05/17 / #20170000873

Dimethyl fumarate and vaccination regimens

Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., DMF) for a first dosing period; (b) administering a vaccine; and... Biogen Ma Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Biogen Ma Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Biogen Ma Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###